A Major Lineage of Enteroendocrine Cells Coexpress CCK, Secretin, GIP, GLP-1, PYY, and Neurotensin but Not Somatostatin.

Egerod, Kristoffer L; Engelstroft, Maja S; Grunddal, Kaare V; Nøhr, Mark K; Secher, Anna; Sakata, Ichiro; Pedersen, Jens; Windeløv, Johanne A; Füchtbauer, Ernst-Martin; Olsen, Jørgen; Sundler, Frank; Christensen, Jan P; Wierup, Nils; Olsen, Jesper V; Holst, Jens J; Zigman, Jeffrey M; Poulsen, Steen S; Schwartz, Thue W

Published in:
Endocrinology

DOI:
10.1210/en.2012-1595

2012

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
A Major Lineage of Enteroendocrine Cells Coexpress CCK, Secretin, GIP, GLP-1, PYY, and Neurotensin but Not Somatostatin


Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology (K.L.E., M.S.E., K.V.G., M.K.N., T.W.S.), Section for Translational Physiology (J.P., J.A.W., J.J.H., S.S.P.), Faculty of Health Sciences, University of Copenhagen, 2200 Denmark; Laboratory for Molecular Pharmacology (K.L.E., M.S.E., K.V.G., M.K.N., T.W.S.), Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, 2200 Denmark; Novo Nordisk Foundation Center for Protein Research, Department of Proteomics (A.S., J.V.O), Faculty of Health Sciences, University of Copenhagen, 2200 Denmark; Division of Hypothalamic Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Department of Biomedical Sciences (J.P., J.A.W., J.J.H., S.S.P.), Department of Cellular and Molecular Medicine (J.O.), Department of International Health, Immunology and Microbiology (I.P.C.), University of Copenhagen, 2200 Denmark; Department of Molecular Biology (E.-M.F.), University of Aarhus, 2200 Denmark; and Department of Clinical Sciences in Malmö (F.S., N.W.), Lund University Diabetes Center, Malmö, 205 02, Sweden

Enteroendocrine cells such as duodenal cholecystokinin (CCK cells) are generally thought to be confined to certain segments of the gastrointestinal (GI) tract and to store and release peptides derived from only a single peptide precursor. In the current study, however, transgenic mice expressing enhanced green fluorescent protein (eGFP) under the control of the CCK promoter demonstrated a distribution pattern of CCK-eGFP positive cells that extended throughout the intestine. Quantitative PCR and liquid chromatography-mass spectrometry proteomic analyses of isolated, FACS-purified CCK-eGFP-positive cells demonstrated expression of not only CCK but also glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), peptide YY (PYY), neurotensin, and secretin, but not somatostatin. Immunohistochemistry confirmed this expression pattern. The broad coexpression phenomenon was observed both in crypts and villi as demonstrated by immunohistochemistry and FACS analysis of separated cell populations. Single-cell quantitative PCR indicated that approximately half of the duodenal CCK-eGFP cells express one peptide precursor in addition to CCK, whereas an additional smaller fraction expresses two peptide precursors in addition to CCK. The coexpression pattern was further confirmed through a cell ablation study based on expression of the human diphtheria toxin receptor under the control of the proglucagon promoter, in which activation of the receptor resulted in a marked reduction not only in GLP-1 cells, but also PYY, neurotensin, GIP, CCK, and secretin cells, whereas somatostatin cells were spared. Key elements of the coexpression pattern were confirmed by immunohistochemical double staining in human small intestine. It is concluded that a lineage of mature enteroendocrine cells have the ability to coexpress members of a group of functionally related peptides: CCK, secretin, GIP, GLP-1, PYY, and neurotensin, suggesting a potential therapeutic target for the treatment and prevention of diabetes and obesity. (Endocrinology 153: 5782–5795, 2012)
Hormone-producing enteroendocrine cells are scattered throughout the gastrointestinal (GI) tract from the esophagus to the rectum, collectively constituting the largest and most diverse endocrine organ of the body (1–4). Enteroendocrine cells are generally flask shaped with an apical, microvillus-decorated sensory extension reaching the gut lumen and with dense core secretory granules at the base from which the gut hormones are released (5–7). About 15 different types of enteroendocrine cell types have been identified, and a similar, large number of peptide hormones have been assigned to each distinct cell type. Enteroendocrine cells were originally defined on the basis of distinct electron microscopic characteristics of their secretory granules (8). However, immunohistochemistry soon revealed that different enteroendocrine cell types could be distinguished by expression of distinct peptide hormones. For example, the so-called I-cells and S-cells of the duodenum were found to store cholecystokinin (CCK) and secretin, respectively (6, 9, 10), whereas enteroglucagon and later glucagon-like peptide 1 (GLP-1) were found in the L-cells of the ileum (11). At present, it is still generally assumed that each enteroendocrine cell type stores and releases peptide hormones derived from only a single peptide hormone precursor. Well-established exceptions to this concept are few and include L-cells, which costore and corelease GLP-1 and GLP-2 (both derived from post-translational processing of proglucagon) and peptide YY (PYY) (12, 13).

Enteroendocrine cells differ from other peptide hormone- and neuropeptide-producing endocrine and neuronal cells in the body in that they continuously are renewed, with a generation time of only 5–7 d (14, 15). Importantly, all the enteroendocrine cell types, as well as all other cell types of the GI tract epithelium, are derived from single pluripotent stem cells residing in the mucosal crypts. These stem cells divide to give rise to a pool of rapidly dividing transit-amplifying cells, which enter either an absorptive or a secretory lineage as they reach the upper crypt region (16–18). The enteroendocrine cells are derived from a secretory lineage that is dependent upon the expression of ngn3 (19). During maturation, most enteroendocrine cells, as well as goblet cells and absorptive enterocytes, migrate upward in the crypt, whereas Paneth cells migrate to the bottom of the crypt and have a longer generation time (1). Before leaving the crypts, enteroendocrine cells are believed to become terminally differentiated, such that each mature subtype produces only peptides derived from a single peptide hormone precursor. It was noted early on, however, that a subpopulation of enteroendocrine cells migrate downward in the crypts to reside close to the LGR5-positive progenitor and Paneth cells (20–22). These enteroendocrine cells located deep in the crypts are known to coexpress a broad selection of gut hormones: CCK, secretin, gastric inhibitor peptide (GIP), and neurotensin as well as stem cell markers (20). In contrast, the enteroendocrine cells, which migrate up into the villi, comply with the current one cell-one hormone dogma for enteroendocrine cells (1, 14, 15, 20).

The present study was undertaken to better characterize CCK cells, which previously had been thought to be limited to the duodenum. Using primarily material from transgenic reporter mice expressing enhanced green fluorescent protein (eGFP) under the control of the CCK promoter, we demonstrate both a more widely distributed expression pattern of CCK cells throughout the GI tract and coexpression of functionally related gut hormones (i.e. GLP-1, PYY, GIP, secretin, and neurotensin) with CCK. The coexpression was not limited to enteroendocrine cells in the crypts but was also found in presumably mature enteroendocrine cells of the villi. We did not detect coexpression of CCK with the functionally distinct peptide somatostatin. Expression of peptides derived from more than one preprohormone in the same enteroendocrine cell was further verified through a cell ablation study using transgenic mice in which the human diphtheria toxin receptor is expressed under the control of the glucagon promoter. Key elements of the coexpression were demonstrated also in the human small intestine by double staining immunohistochemistry.

Materials and Methods

Transgenic mice

Cck-eGFP transgenic mice were developed by the Gensat project (www.gensat.org) and obtained from the Mutant Mouse Regional Resource Center.

Humanized Renilla green fluorescent protein (Ghrelin-hrGFP) (line hrGFP10) mice were generated as previously described (23).

Gcg-hDTR mice were generated using a bacterial artificial chromosome (BAC) clone (RP23-343C17) in which the sequence coding for the human diphtheria toxin receptor was inserted at the start codon for Gcg. The mice were generated at DAGMAR (Danish Genetically Modified Animal Resource).

All animal studies were carried out in accordance with the Institutional Animal Care and Use Committees at the Universities of Copenhagen and Texas Southwestern Medical Center.

Cell isolation and FACS purification

Intestinal CCK cell isolation and purification

Cck-eGFP transgenic mice were euthanized and duodenal, jejunal, and ileal segments were inverted, inflated, and digested for 20 min with 0.13 Wünsch units of Liberase (Roche, Indianapolis, IN) in DMEM 1885 while being slowly shaken at 37 C. Every fifth minute the tissue was shaken vigorously for 5 sec. This
procedure was repeated three times. Before sorting, the cells were slowly shaken for a second period of 20 min at 37 C, passed through a 70-μm pore diameter cell strainer, pelleted at 1500 rpm for 5 min, and resuspended in DMEM 1885 with 10% fetal bovine serum.

Fractionation of crypt vs. villus cells

Similar to the method developed by Stegmann et al. (24), we fractionated cells using the procedure described above; importantly, during the first 20-min period the vigorous shaking every fifth minute was replaced by a gentle inverting of the tube 10 times. Cells liberated during this first enzyme digestion were used as the villus fraction. Over the next 35 min the tissue was shaken vigorously every fifth minute and cells liberated were discarded. A final incubation for 20 min with fresh enzyme solution yielded the crypt fraction. The crypt and villus fractions were verified by QPCR for markers for the villus (Alpi and Apo4) and crypt (Lyz1 and Defa5). Primers are listed in Supplemental Table 1.

Gastric ghrelin cell isolation and FACS purification

hrGFP-positive and negative cells were isolated and FACS purified from ghrelin-hrGFP mice as previously described (23).

RNA extraction and quantitative RT-PCR analysis

Total RNA was extracted from 5000–30,000 cells using NucleoSpin RNA XS kit (Macherey-Nagel, Duren, Germany), and RT-PCR was performed using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA). Custom-designed StellAR-ray qPCR arrays (Lonza Group, Basel, Switzerland) were assayed according to the manufacturer’s instructions with SYBR Premix Ex Taq (TaKaRa, Otsu, Shiga, Japan), pictures were captured with a CMOS camera (ProRes CT3 USB, Jenoptik). Target regions are listed in Supplemental Table 1.

To enable direct comparison of RNA levels from different genes, a genomic DNA sample containing all assayed transcripts was used as calibrator, and the data were further normalized using Ywhaz as reference gene as previously described (25).

Single-cell quantitative RT-PCR analysis

Single cells from duodenum were sorted directly into 10 μl 2 × RT buffer (100 mM Tris, 150 mM KCl, 6 mM MgCl2, 10 mM dithiothreitol) in 96-well plates using a BD FACS Aria II (BD Biosciences, Palo Alto, CA) or a MoFlo XDP (Beckman Coulter, Brea, CA). Cells were sorted on dry ice or into lysis buffer for RNA extraction or into 6M acetic acid for peptide analysis.

Intestinal tissue from Cck-eGFP transgenic mice

Tissue was fixed in freshly prepared 4% paraformaldehyde (24 h at 4 C), followed by 2 d cryoprotection (20% sucrose at 4 C). The tissues were embedded in Tissue-Tek (Sakura Finetek, Torrance, CA), snap frozen in isopentane and stored at −20 C. (8 μm) Sections were cut with a cryostat (cm3050 S, LEICA) and placed on glass slides to air dry for 1 h at room temperature, washed three times for 5 min. in PBS. Sections were preblocked using 2% BSA in PBS for 1 h and incubated overnight at 4 C with the primary antibodies (Supplemental Table 2). The primary antibodies were washed off (three times for 5 min, PBS) and replaced by secondary antibodies (Supplemental Table 2) and incubated 1 h at room temperature. Secondary antibodies were washed off, and PBS containing Hoechst stain (Thermo Scientific, Rockford, IL) was added for 5 min. The sections were washed (three times for 5 min) in PBS and coverslipped in mounting medium (S3023; DAKO Corp., Carpenteria, CA). Using a fluorescence microscope (Olympus IX70, Olympus Corp., Lake Success, NY), pictures were captured with a CMOS camera (ProRes CT3 USB, Jenoptik).

Ablation study and immunohistochemistry on Gcg-hDTR transgenic mice

Transgenic Gcg-hDTR and WT mice (20 wk of age) received ip injections of diphtheria toxin (100 ng/g bodyweight) (Sigma Aldrich, St. Louis, MO). Mice were killed at time zero or 24 h after diphtheria toxin administration. Twenty cross-sections of distal ileum tissue were collected for each peptide and mice analyzed (five cross-sections from four interspaced positions). All cells staining positive for a given peptide were counted and finally normalized as counts per cross-section. The tissue was excised and submerged into freshly prepared 4% paraformaldehyde for 48 h at 4 C, stored in 70% alcohol, and paraffin embedded using a Shandon Excelsior (Thermo Fisher). Sections (4–6 μm) were cut and dried (60 C, 1 h) and stored at 4 C. Sections were deparaffinized, rehydrated, and boiled for 15 min in 0.01 mol/liter citrate buffer (pH 6.0). Tissue sections were permeabilized with PBST [PBS-Ca-Mg (pH 7.4) + 0.1% Triton] three times for 2 min. Sections were preblocked using 2% BSA (15 min room temperature) and incubated overnight at 4 C with the primary antibodies (Supplemental Table 2), washed in PBS (three times 2 min), and incubated for 1 h with biotinylated secondary anti-
Endogenous tissue peroxidase was blocked using 3% H$_2$O$_2$ in PBS for 8 min followed by 30-min incubation in vectastain reagents (Vector Laboratories, Burlingame, CA) and 15-min incubation with freshly made 3,3 diaminobenzidine solution (Kementec Diagnostics, Copenhagen, Denmark). Aqueous solution of CuSO$_4$ in TNT buffer (0.1M Tris-HCl, 0.15M NaCl, and 0.05% Tween 20) was applied for 1 min to enhance coloration. Slides were counterstained with Mayer’s hematoxylin (Ampliqon, Odense, Denmark), dehydrated in alcohol, and coverslipped with Pertex (catalog no. 00801; Histolab, Gothenburg, Sweden).

**Immunohistochemistry of human small intestinal tissue**

Untraceable historical archival samples of normal human intestinal tissues that were originally collected during surgery of the GI tract were used. Immunohistochemistry in these paraffin-embedded tissues were performed in a manner similar to that described above for mice tissues.

**Results**

**Immunohistochemical analysis of eGFP expression in CCK-eGFP mice**

CCK has previously been identified as mainly a duodenal hormone. Accordingly, eGFP expression was found in classical enteroendocrine-like cells scattered in the duodenal mucosa from CCK-eGFP transgenic mice. These CCK-eGFP-positive cells were located both in the crypts and villi (Fig. 1A). As in previous reports, the majority of these duodenal eGFP-positive cells contained CCK immunoreactive material (28–30). A relatively large population of CCK-eGFP-positive enteroendocrine cells was observed in the jejunum, and surprisingly, also in the ileum and colon, where classical CCK cells were not expected to be found in great numbers (Fig. 1, B–D). A small fraction of the CCK-eGFP-positive enteroendocrine cells did not contain CCK immunoreactivity (Fig. 1, E–G); these were characterized further by single-cell QPCR analysis (see below).

**QPCR analysis of isolated FACS-purified CCK-eGFP positive cells**

To characterize the CCK-eGFP-positive cells in more detail, single cell preparations were generated through enzymatic digestion of mucosa from different segments of the small intestine, followed by FACS (Fig. 2A). The CCK-eGFP-positive cells constituted on average 0.2% of cells released from the duodenal mucosa by enzymatic digestion. After FACS sorting, the CCK-eGFP-positive cells were more than 90% pure as judged by microscopy. QPCR analysis revealed that the CCK-eGFP-positive cells purified from duodenum expressed RNA coding for the CCK precursor (Cck), as expected (Fig. 2B). The expression of Cck was enriched 250-fold in the CCK-eGFP-positive cells compared with the eGFP-negative cells (Fig. 2B). Unexpectedly, the CCK-eGFP-positive cells expressed equal amounts of RNA encoding the secretin precursor (Sct) as that encoding Cck. They also expressed relatively large amounts of Gip and ghrelin (Ghrl) RNA, i.e., about half and one fourth of Cck RNA, respectively (Fig. 2B). RNA encoding the proglucagon/GLP-1 precursor (Gcg), the neurotensin (Nts) precursor, and the Pyy precursor were also detected in the CCK-eGFP-positive cells from duodenum albeit at relatively low copy numbers compared with Cck (Fig. 2B). In contrast, RNA encoding somatostatin and substance P precursors were barely detectable (Tac1 in Fig. 2B).

A similar QPCR analysis was performed on FACS-purified CCK-eGFP positive cells from jejunum and ileum. As shown in Fig. 2D, the relative copy number of Cck was much lower in jejunum and ileum compared with duode-
num, in accordance with the expected overall expression pattern for the CCK hormone. Similarly, the expression of Ghrl was much lower in cells from the jejunum compared with the duodenum and basically was not present in cells from the ileum (Fig. 2D). Gip RNA expression in the eGFP-positive cells was similar in jejunum as is duodenum, but much lower in the ileum. In contrast, secretin was expressed at almost the same level in the CCK-eGFP-positive cells from both jejunum, ileum, and duodenum (Fig. 2E) (3). It should be noted that the expression profiles shown in Fig. 2, D and E, correspond to the expression of the RNA coding for these peptide precursors in the CCK-eGFP-positive cells, not their general expression profile in the mucosa as such.

Thus, although CCK is the most highly expressed peptide hormone at the RNA level in the CCK-eGFP-positive cells in the duodenum, a number of other peptides including secretin are expressed to a similar level within these cells. Unexpectedly, purified CCK-eGFP-positive cells from the jejunum and ileum express nearly the same amount or more of Sct, Nts, Gcg, and Pyy than Cck itself.

QPCR analysis of ghrelin-hrGFP positive cells from the stomach

To probe whether the relatively broad expression pattern of gut hormones is a phenomenon related to the BAC GFP reporter approach as such, we applied the QPCR array for peptide hormones to FACS-purified ghrelin cells isolated from the gastric mucosa of transgenic ghrelin-hrGFP mice prepared as previously reported (23). Similar to the CCK-eGFP line on which the current manuscript is focused, the ghrelin-hrGFP line also was generated by placing a GFP reporter construct under the control of ghrelin transcriptional control elements present in a BAC. As shown in Fig. 2C, a very different, clean expression profile was obtained in gastric ghrelin-hrGFP cells. More
Thus, confirming the QPCR analysis of pooled populations of FACS-separated CCK-eGFP cells, single-cell QPCR of individual cells from those CCK cell-enriched pools demonstrates that a relatively large fraction of duodenal CCK-eGFP-positive cells express more than one hormone gene, of which Sct is dominant. However, only a relatively small fraction of the cells express more than two hormone genes.

**Villus vs. crypt analysis of CCK-eGFP-positive cells**

One explanation for the relatively broad repertoire of peptide hormones being expressed in the CCK-eGFP cells could be that this was mainly a phenomenon occurring in immature cells of the crypts. To assess this, populations of cells derived from duodenal villi or crypts were generated based on the fact that cells from the villi are detached before cells from the crypts during the enzymatic treatment of the mucosa (24). The separation of crypt vs. villus cells was validated by QPCR analysis for control marker enzymes of which lysozyme and Defa5 (both Paneth cell markers), as expected, were highly enriched in the CCK-eGFP-negative cells from the crypts, whereas alkaline phosphatase and ApoA4 (both enterocyte markers), also as expected, were enriched in the CCK-eGFP-negative cells from the villi (Fig. 4A).

Among the peptide hormones, not only Cck but also Sct, Pyy, and Nts were all enriched in the villus compared with the crypt fraction of CCK-eGFP-positive cells, in contrast to Gip, Ghrl, and Gcg, which were relatively evenly expressed in the villus and crypt fractions of CCK-eGFP-positive cells from duodenum (Fig. 4A).

Single-cell QPCR performed on cells isolated either from the villus (Fig. 4B) or the crypt (Fig. 4C) of duodenum supported the notion that the coexpression of multiple peptide hormones in the CCK-eGFP-positive cells is a general phenomenon, which is not limited to cells residing in the crypts.

**Immunohistochemical localization of peptides in CCK-eGFP cells**

The hormonal expression within CCK-eGFP cells at the peptide level was further illuminated by means of performing immunohistochemistry with antibodies selective for each of the discussed peptide hormones.

As shown in Fig. 5, CCK-eGFP-positive cells in the duodenum costained with antibodies against secretin, GIP, GLP-1, neurotensin, and PYY. Approximately 60% of the
secretin-positive cells were CCK-eGFP positive and, interestingly, these cells occasionally were found clustered within the same crypt-villus segment (Fig. 5 and see Fig. 7). A relatively large fraction of the rather scarce PYY- and GLP-1-positive cells were also positive for CCK-eGFP. CCK-eGFP-positive cells costaining with antibodies for the various non-CCK peptide hormones were not only found in the crypts but frequently also along the length of the villi (Fig. 5). We did not detect any costaining of CCK-eGFP with antibodies directed against somatostatin, which is in agreement with the QPCR data. Also, no costaining of CCK-eGFP with ghrelin was observed, which, however, was surprising because the QPCR analysis indicated expression of Ghr1 mRNA in FACS-separated CCK-eGFP-positive cells (Fig. 2B).

It is concluded that subpopulations of the CCK-eGFP-positive cells costore secretin, GLP-1, PYY, GIP, and neurotensin peptides, but apparently not somatostatin- and ghrelin-immunoreactive material.

**LC-MS analysis of peptides from FACS-purified CCK-eGFP cells**

To study the occurrence of the peptides in the CCK-eGFP-positive cells more directly, acetic acid extracts of FACS-purified CCK-eGFP cells from the whole small intestine were subjected to LC-MS analysis using an LC protocol for small to medium peptides. The purity of the preparation was substantiated by the fact that the top nine scoring proteins, based on the sum of the single peptides recorded in the LC-MS analysis, all were derived from either gut hormone precursors or prograins. Among the granins, peptides from secretogranin-1 (chromogranin-B), secretogranin-2, and chromogranin-A were detected in the CCK-eGFP-positive cells in numbers and with a total intensity corresponding to the peptide precursors (Table 1).

With respect to peptides derived from hormone precursors, the pro-CCK peptides were dominating both in terms of number and total peptide MS intensity; 68 pro-CCK-derived peptides with a total peptide intensity signal of $4.1 \times 10^8$ were observed (Table 1). Additionally, 34 peptides from pro-glucagon/GLP-1 were detected in the extracts of the CCK-eGFP-positive cells giving a total intensity of $2.4 \times 10^8$. Similarly, a large number of peptides derived from pro-neurotensin, pro-PYY, and pro-GIP gave total intensities in the same order of magnitude as pro-CCK and proglucagon/GLP-1 (Table 1). However, in view of the dominating position of Sct RNA in the QPCR analysis, only relatively small amounts of peptides derived from prosecretin were detected, i.e., $0.2 \times 10^8$, which is just above the intensity of the first contaminating proteins, keratin (Table 1). Proghrelin (two peptides with an intensity of $1.1 \times 10^6$) and prosomatostatin peptides were only found in...
what was considered to be noise level, in accordance with the immunohistochemical data (Fig. 5).

At the proteomics level, it is concluded that the CCK-eGFP-positive cells contain not only pro-CCK-derived peptides, but also relatively large amounts of peptides derived from especially proglucagon, pro-GIP, proneurotensin, and to a lesser degree prosecretin.

Cell ablation based on proglucagon promoter-driven diphtheria toxin receptor expression

In mice expressing the human diphtheria toxin receptor under the control of the proglucagon promoter, treatment with diphtheria toxin eliminated nearly all GLP-1 cells in the mucosa of the ileum within 24 h (Fig. 6A). As expected based on the previously well-characterized coexpression of GLP-1 with PYY, PYY-containing cells were ablated to an almost similar extent. Based on the above immunohistochemistry, QPCR, and LC-MS studies, it was not surprising that treatment with diphtheria toxin also resulted in a marked reduction in CCK cells (Fig. 6B). It was not expected that reductions in neurotensin cells, GIP cells, and secretin cells would also be observed (Fig. 6, A–C). Numbers of somatostatin cells and substance P cells were unaffected (Fig. 6 and Supplemental Fig. 1). These changes seemingly were not due to a generalized diphtheria toxin-induced gut mucosal injury because no obvious histological changes to the mucosal appearance were observed (Supplemental Fig. 1).

These experiments indicate that the proglucagon promoter is active not only in GLP-1-producing cells, but also in the majority of PYY, neurotensin, and GIP cells and a major fraction of the CCK and secretin cells, but not in the somatostatin and substance P cells.

Costaining of peptide hormones in human enteroendocrine cells

The above data relate to murine tissues and are based on cells genetically tagged by GFP or diphtheria toxin re-
ceptor. To probe for similar coexpression patterns within human tissues, we used classical double-staining immunohistochemical analysis employing combinations of rabbit and goat antisera raised against the gut peptide hormones. Inclusion criteria for commercial goat-derived antibodies were that they should show identical staining patterns of enteroendocrine cells as our prevalidated rabbit antibodies (Supplemental Fig. 2).

Here we focused on costaining experiments based on CCK and secretin, respectively. In the human duodenum, CCK immunoreactivity was found in almost all GIP-positive cells, which mainly were located in the crypts (Fig. 7). Nevertheless, most CCK-positive cells did not store GIP. In contrast, CCK immunoreactivity was found in at least 50% of the human duodenal secretin cells, mainly in the villi, and in nearly all duodenal PYY cells, which were few in number. In the jejunum, CCK also was found in many neurotensin-positive cells and in the majority of the GLP-1-positive cells.

The other major duodenal hormone, secretin, was costored with GIP in the majority of human duodenal GIP-positive cells, again mainly in the crypts. In the human jejunum, secretin immunoreactivity was found to be costored with neurotensin, mainly in the villi. In the ileum, secretin was found in the majority of GLP-1-positive cells, mainly in the crypts but also in the villi (Fig. 7).

In contrast, somatostatin cells were observed throughout the human gut, and we did not observe costaining of somatostatin with any of the other hormones tested. This lack of costaining of somatostatin with other gut hormones is shown for CCK in the duodenum in Supplemental Fig. 3; however, costaining of ghrelin with other tested gut hormones was not observed. The motilin gene is not found in the mouse and rat, where ghrelin alone is thought to control, for example, gut motility, which in many other animals conceivably is taken care of by the two peptides jointly.

Although not comprehensive, this immunohistochemical analysis demonstrates coexpression and costorage of CCK, secretin, GIP, GLP-1, PYY, and neurotensin in subsets of enteroendocrine cells of the human small intestine, not only in the crypts but also on the villi. In contrast, but in agreement with the mouse data, no indication of coexpression of somatostatin or ghrelin with this larger group of gut hormones was observed.

**Discussion**

According to textbooks, CCK is a peptide hormone expressed and released from I-cells of the duodenum and, to some extent, the jejunum (4, 6, 32–35). CCK cells are not generally believed to be found throughout the GI tract, nor are they expected to store and release other biologically active peptides other than CCK, such as GLP-1. It was

<table>
<thead>
<tr>
<th>Peptide precursor</th>
<th>Total peptide intensity</th>
<th>No. of different peptides</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procholecystokinin</td>
<td>$4.1 \times 10^8$</td>
<td>68</td>
</tr>
<tr>
<td>Proglucagon</td>
<td>$2.4 \times 10^8$</td>
<td>34</td>
</tr>
<tr>
<td>Prosecretogranin-1</td>
<td>$2.3 \times 10^8$</td>
<td>49</td>
</tr>
<tr>
<td>Proneurotensin</td>
<td>$1.6 \times 10^8$</td>
<td>18</td>
</tr>
<tr>
<td>Pro-PYY</td>
<td>$1.2 \times 10^8$</td>
<td>26</td>
</tr>
<tr>
<td>Pro-GIP</td>
<td>$0.9 \times 10^8$</td>
<td>34</td>
</tr>
<tr>
<td>Prosecretogranin-2</td>
<td>$0.7 \times 10^8$</td>
<td>42</td>
</tr>
<tr>
<td>Prochromogranin-A</td>
<td>$0.7 \times 10^8$</td>
<td>22</td>
</tr>
<tr>
<td>Prosecretin</td>
<td>$0.2 \times 10^8$</td>
<td>18</td>
</tr>
<tr>
<td>Keratin, type II</td>
<td>$1.6 \times 10^7$</td>
<td>38</td>
</tr>
<tr>
<td>Cytoskeletal 8</td>
<td>$0.1 \times 10^7$</td>
<td>8</td>
</tr>
</tbody>
</table>

The number of peptide fragments from each of the peptide precursors and the total intensity of these peptides are indicated.
therefore surprising to find substantial numbers of CCK-eGFP-positive cells in regions of the small and large intestines other than the duodenum and jejunum, as we report here. Furthermore, it was surprising to find that CCK cells express not only relatively high levels of RNA encoding peptide precursors in addition to CCK, but also that they store peptides derived from these precursors. Similarly, GLP-1 is generally believed to be expressed mainly in a limited population of enteroendocrine cells of the lower small intestine and the colon (35). However, as observed in the CCK-eGFP reporter mice, we found through diphtheria toxin-mediated cell ablation that the proglucagon promoter is active not only in GLP-1 and PYY cells, but also in neurotensin and GIP cells as well as CCK and secretin cells of the ileum.

Importantly, a similar broad peptide coexpression phenomenon could be demonstrated by classical immunohistochemical costaining in the human small intestine, totally independent of any transgenic methodology.

A series of reports on transgenic reporter mice expressing variants of GFP under the control of promoters for different gut peptide precursors have been published over the last couple of years without mention of coexpression of nonexpected peptide hormones (23, 28, 36, 37). However, very recently, Habib et al. (38) reported that FACS-purified GLU-Venus (proglucagon-Venus) and GIP-Venus cells also express both RNA and immunoreactive peptides corresponding to the precursors for CCK, GIP, and secretin. This broad peptide hormone expression pattern corresponds rather closely to what we find in the present study for CCK-eGFP cells and proglucagon-hDTR cells.

Is the apparent coexpression a phenomenon related to the transgenic BAC-based labeling technology?

Such a genetic tagging artifact possibly could explain the observed broad peptide coexpression pattern described in the present study and that of Habib et al. (38). The expression of CCK-eGFP in cells apparently not expressing CCK itself could indicate such an artifact,
which according to the single-cell QPCR analysis is observed in 9–12% of the enterendocrine cells (Figs. 3 and 4). In principle, this could be a result of ectopic expression of the CCK-eGFP in non-CCK cells. However, it could also reflect that the QPCR reaction for CCK has failed in 9–12% of the wells, although CCK mRNA was present (the QPCR is performed in an unamplified manner on very little RNA material). Or, another likely possibility could be that the highly stable eGFP molecule is still present in mature enterendocrine cells that no longer express CCK but did express CCK, and CCK-eGFP, earlier in their life cycle, i.e., in the crypts (39). Moreover, gastric ghrelin cells derived from a line of ghrelin-hrGFP transgenic mice, which was made by a similar transgenic approach, showed no sign of expression of enterendocrine peptide hormones other than ghrelin (Fig. 2). Importantly however, ectopic expression of the eGFP reporter in cells other than CCK cells or the occurrence of stable eGFP in mature cells that no longer express Cck would not explain the single-cell QPCR data in which 44% of the individual cells containing Cck RNA, which happen to have been isolated from CCK-eGFP mice based on their eGFP signature, were found also to contain Sct RNA, Gip RNA, ghrelin RNA, or combinations of those (Fig. 3). Furthermore, key components of the coexpression phenomenon were confirmed in human tissue samples using classical immunohistochemical double-labeling technique, which is totally independent of the GFP labeling technology (Fig. 7).

**Does the QPCR coexpression reflect an RNA phenomenon not carried over to the protein level?**

This is clearly not the case for the majority of the peptides studied as demonstrated by the immunohistochemical and LC-MS proteomic studies. However, in the case of ghrelin and secretin, the coexpression phenomenon is exclusively or to a large extent observed at the RNA level compared with the protein level. Thus, although coexpression of ghrelin RNA with Cck mRNA was observed in the CCK-eGFP-enriched intestinal enterendocrine cell pools as well as in individual CCK-eGFP cells (Figs. 2 and 3), we observed only minimal, if any, immunohistochemical coexpression of ghrelin with the other peptides. These immunohistochemical observations agree well with the finding that proghrelin peptides were not detected above the noise level in the LC-MS analysis of FACS-separated CCK-eGFP cells (Table 1). Similarly, very few and only small amounts of prosecretin peptides were detected in the LC-MS analysis, which contrasted with the high levels of secretin RNA observed in the CCK-eGFP-positive cells even in the jejunum and ileum, where the secretin peptide is not normally believed to be expressed (Fig. 2). Nevertheless, and in contrast to ghrelin, secretin could by immunohistochemistry be detected in CCK-eGFP-positive cells, and colocalization of CCK and secretin was detected by costaining experiments in the human tissue samples (Fig. 6). The LC-MS data, however, do indicate that the secretin expression must be rather low at the protein level, e.g., in the distal small intestine.

**Is the coexpression only a crypt phenomenon?**

It has long been known that a subpopulation of enterendocrine cells in the crypts can express multiple peptide hormones (40). This phenomenon was recently described in relation to CCK-eGFP cells (20), as was the observation of expression of only a single hormone within enterendocrine cells localized within the villi, presumably after their migration out of the crypts during the maturation process. In the present study, however, using both immunohistochemistry and QPCR analysis of FACS-separated enriched pools of CCK-eGFP cells or of individual FACS-separated CCK-eGFP cells, isolated from either villi or crypts, demonstrated that the coexpression phenomenon clearly is not restricted to the crypts, but is found in the presumed mature cells that populate the villi, as well. Concerning the FACS analysis, we did not exclude the possibility that expression of CCK-eGFP in the enterendocrine cells potentially could have affected the expression of the marker enzymes in the enterocytes and Paneth cells.

**Cell ablation studies also demonstrate extensive coexpression of more than one peptide hormone within enterendocrine cells**

Our cell ablation study based on the proglucagon promoter-driven expression of human diphtheria toxin receptor supports the phenomenon of a broader existence of enterendocrine cells with coexpression of gene products from more than one peptide hormone precursor. Not only did this system support the above studies demonstrating coexpression of CCK with GLP-1, but it also demonstrated the existence of cells in which proglucagon-derived peptide hormones were coexpressed with several other peptide hormones.

Previously, Rindi et al. (41) performed a similar cell ablation study aimed at secretin-producing enterendocrine cells using transgenic expression of the thymidine kinase from herpes simplex virus under the control of the secretin promoter. Similar to our study, they observed markedly reduced numbers of not only secretin cells, but also CCK, GLP-1, and PYT cells and also, to some degree, GIP cells during ganciclovir treatment. However, because Rindi et al. treated with the toxic prodrug for 5 d, their study could only indicate that the secretin gene is expressed in a progenitor cell, which is common to a number of enterendocrine cell types (41).
Broad coexpression of gut hormones has been reported previously

Although the one cell-one hormone concept has been the prevailing dogma in enteroendocrinology, there are, in fact, strong reports in the literature describing a broad coexpression of peptide hormones similar to what we find in the present study (22, 40, 43). As early as 20 years ago, pioneering transgenic work of Roth et al. (40), combined with classical immunohistochemical techniques, demonstrated that colonic enteroendocrine cells not only share a cellular origin, but also coexpress several gut hormones, even as mature cells. Based on pair-wise comparison of coexpression, they suggested that the colonic enteroendocrine lineage has two branches: one branch produces substance P cells and another branch produces CCK, GLP-1, PYY, and neurotensin cells (40). The latter enteroendocrine lineage or branch very likely corresponds to the lineage identified in the present study in the small intestine, which we find expresses also GIP and secretin, but not somatostatin, and, at the protein level, not ghrelin. Antibodies against the latter four hormones were not employed in the cited study (40).

Proposed model of small intestinal enteroendocrine cell lineage

In the context of the results of the present study, which takes a broad spectrum of peptides into account, it would appear that there are two main lineages of enteroendocrine cells in the small intestine: one lineage yielding cells expressing the universally inhibitory peptide hormone somatostatin, and a second lineage that includes cells that have the potential of coexpressing CCK, GLP-1, GIP, PYY, neurotensin, and secretin. Some of the major functions of the peptide products are indicated above each cell lineage.

**FIG. 8.** Schematic overview of proposed main enteroendocrine cell lineages of the small intestine. Based on the results of the present study as well as studies by Roth et al. (40), it is suggested that cells expressing the universally inhibitory peptide somatostatin constitute a separate cell lineage distinct from the cell lineage generating cells expressing the rest of the GI-tract peptide hormones. From the latter lineage are apparently generated enterochromafin cells that express substance P (and 5HT) (40), and cells coexpressing ghrelin and motilin (31) plus a major lineage of enteroendocrine cells that have the potential of expressing the functionally related peptides: CCK, secretin, GIP, GLP-1/-2, PYY, and neurotensin. Some of the major functions of the peptide products are indicated above each cell lineage.
Major parts of the old gut hormone physiology remain valid

The results of the present study, as well as, for example, the studies by Roth et al. (40) and Habib et al. (38), do not change the basic physiological concept that CCK is mainly a duodenal hormone, whereas GLP-1, neurotensin, and PYY are mainly hormones of the jejunum and ileum. Such is clearly observed, for example, at the RNA level in CCK-eGFP cells isolated from the different parts of the small intestine (Fig. 2). It is nevertheless apparent from these studies that enteroendocrine cells have a much broader potential for expression of multiple peptide precursors than is generally believed. Our single-cell QPCR data of CCK-eGFP-labeled cells indicates that in a given cell this potential is, however, only exploited to a limited degree because coexpression of more than one hormone was observed in only half of the cells and expression of more than two hormone genes only rarely was observed (Fig. 3). More studies using other types of approaches and techniques are needed to address the issue of whether a given enteroendocrine cell population in a given location stores and releases peptides from more than one peptide precursor at physiologically meaningful levels.

The enteroendocrine system may be rather adaptive

The apparent, quite broad potential for coexpression of multiple peptide precursors indicates that the enteroendocrine system could be more adaptive than previously believed. The fact that peptide hormones such as CCK, secretin, GIP, GLP-1 and -2, PYY, and neurotensin, to various degrees, are coexpressed in enteroendocrine cells throughout the intestine suggests that the expression pattern potentially could be modulated by environmental factors. This might occur, for example, after bariatric surgery. In principle, such a potential plasticity of the enteroendocrine system could be exploited therapeutically by developing methods to control not only the secretion of the peptide hormones, but also methods to control the number and types of enteroendocrine cells or the ability of a certain enteroendocrine cell type to express a different, given repertoire of peptides, which they already are equipped to express. This will require insight into the factors and receptors that may control the peptide precursor expression pattern and the precursor processing pattern of the enteroendocrine cells.

Acknowledgments

We thank Professor Bente Pakkenberg and Ph.D. student Anna Schou Karlsen for essential insights into stereology; and Professors Jens F. Rehfeld, Jan Fahrenkrug, and Ove Schaffalitzky de Muckadell for the generous gifts of antibodies. We also thank laboratory technicians Lisbeth E. Stolpe, Heidi M. Paulsen, Lise S. Strange, Lotte Laustsen, Susanne Hummelgaard, Jovin Suku, and Mette Simons and personnel at the University of Texas Southwestern Medical Center Flow Cytometry Multi-user Core Facility for expert technical assistance.

Address all correspondence and requests for reprints to: Thue W. Schwartz, Laboratory for Molecular Pharmacology, The Panum Institute, Building 18.5, University of Copenhagen, Blegdamsvej 3, Copenhagen, DK-2200, Denmark. E-mail: tws@sund.ku.dk.

This work was supported by The Novo Nordisk Foundation Center for Basic Metabolic Research (www.metabol.ku.dk) including an International Research Alliance with J.M.Z. is supported by an unconditional grant from the Novo Nordisk Foundation. The project was also supported by the UNIK project for Food, Fitness & Pharma (http://www.foodfitnesspharma.ku.dk) from the Danish Ministry of Science, Technology and Innovation. The laboratories were further supported by grants from the Novo Nordisk Foundation (to T.W.S. and N.W.) the Lundbeck Foundation (to K.L.E., and T.W.S.), from the Danish Medical Research Council (to K.L.E., and T.W.S.), the Swedish Medical Research Council (projects nos. 522-2008-4216 and K2009-55 × 21111-01-4 to N.W.) as well as the FP7 Full4Health consortium (for J.J.H.).

Disclosure Summary: The authors have nothing to disclose.

References

10. Larsson LI, Sundler F, Alumets J, Hakanson R, Schaffalitzky de Muckadell OB, Fahrenkrug J 1977 Distribution, ontogeny and ul-


43. Mortensen K, Christensen LL, Holst JJ, Orskov C 2003 GLP-1 and GIP are colocalized in a subset of enteroendocrine cells in the small intestine. Regul Pept 114:189–196

44. De Smet B, Mitsuola A, Depoortere I 2009 Motilin and ghrelin as prokinetic drug targets. Pharmacol Ther 123:207–223